Vaccine adverse reactions increased by 860 per day… Cumulative 7 deaths

One more death report today… 1 convulsion-6 suspicions of anaphylaxis increased

Death-vaccination association cannot be confirmed… Evaluated through Bang Dae-bon, damage investigation team, etc.

On the morning of the 3rd, a medical team dedicated to the treatment of Corona 19, who completed vaccination at the Honam vaccination center, installed in the Uiseong Hall of Chosun University Hospital in Dong-gu, Gwangju, is observing whether there is any adverse reaction.

The number of reported adverse reactions after vaccination against the novel coronavirus infection (Corona 19) increased by 860 a day.

According to the Central Defense Countermeasure Headquarters (Bang Dae-bon) and the Corona 19 Vaccination Response Team (Promotion Team) on the 5th, adverse reactions newly received, including 1 new death, 6 suspicions of’anaphylaxis’, and 1 convulsions as of 0 o’clock on the day. The total number of suspicious reports is 860. As a result, the cumulative number of suspicious reports of adverse reactions since the start of vaccination on the 26th of last month reached 1,578. This is about 0.70% of the 225,853 cumulative inoculations as of 0 o’clock on that day.

The number of reported deaths increased to 7 cumulatively, with 2 additional people from the 5 released the day before. According to the promotion team, of the two newly added deaths, Mr. A was a male in his 40s who was hospitalized in a nursing hospital, and it was confirmed that he suffered from an underlying disease. Mr. A received the AstraZeneca vaccine at 3 p.m. on the 2nd and died at 1 p.m. the day before 46 hours. Another deceased, Mr. B, was a man in his 60s who was hospitalized in a nursing hospital, and was also identified as an underlying disease. He died at 8:30 p.m. the day before 54 hours had elapsed after receiving the AstraZeneca vaccine at 2 p.m. on the 2nd. However, Mr. B is scheduled to be officially reflected in statistics as of the 6th as reports of death are received after 0 o’clock on the same day.

The number of suspicious cases of anaphylaxis, a severe systemic allergic reaction, increased to 13, with 6 additional cases. In the case of suspected anaphylaxis, Daebon Bang explained that one case was’anaphylaxis shock’, and the other 12 cases were’anaphylaxis-like reactions’, where the actual serious reaction was not confirmed. Anaphylaxis-like reaction is when symptoms such as shortness of breath and urticaria appear within 2 hours after vaccination. In terms of symptoms, it is similar to anaphylaxis, but it can be improved with symptomatic therapy, experts explain.

Convulsions were also reported for the first time. C, who was reported as a suspected case of convulsion, is a woman in her 40s who is admitted to a nursing hospital, and it was found to have an underlying disease. Mr. C showed fever symptoms 12 hours after receiving the AstraZeneca vaccine at 11 am on the 3rd. After that, a convulsion appeared and was immediately transferred to a general hospital and is currently receiving treatment.

Bang Dae-bon is currently investigating serious cases such as death and anaphylaxis, and plans to hold epidemiological and damage investigation groups to evaluate the causality between death and vaccination. Authorities and experts believe that the association between death and vaccination is low.

Of the 860 new adverse reaction reports, 856 were related to the AstraZeneca vaccine and 4 were related to the Pfizer vaccine. Of the cumulative 1,578 cases, 1,567 were related to the AstraZeneca vaccine and 11 were related to the Pfizer vaccine. To date, no cases of serious adverse reactions have been reported among those vaccinated by Pfizer.

When all cases of adverse reactions are reported as mild or severe, 1,558 out of 1,578 cumulative cases are mild cases such as headache, fever, and nausea, which are common after vaccination. However, if more than one symptom appears, it is possible to report duplicates.

/ Intern reporter Park Yena [email protected]

< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >

Source